A Singapore-based organisation announced Thursday it will develop an Ebola vaccine dubbed the "most promising" to fight back against a deadly outbreak in the Democratic Republic of Congo. Nearly 1,500 people have died in the conflict-wracked African country from the Bundibugyo strain of Ebola, for which there are no vaccines or treatments. Advertisement AdvertisementAdvertisement AdvertisementWorld Health Organization experts have said a single-dose shot based on the rVSV platform is the "most promising" candidate. This is because it uses the same platform as the only officially licenced Ebola vaccine Ervebo, which targets a different strain called Zaire. "We're racing to develop a Bundibugyo vaccine and make doses for clinical trials," Hilleman Laboratories CEO Raman Rao said in a statement.